Article Abstract

Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report

Authors: Bixia Tang, Xinan Sheng, Yan Kong, Zhihong Chi, Lu Si, Chuanliang Cui, Xieqiao Yan, Lili Mao, Bin Lian, Siming Li, Xuan Wang, Jie Dai, Xue Bai, Li Zhou, Jun Guo


The mortality associated with unresectable or metastatic melanoma remains high despite of the emergence of new anti-tumor agents. In this case report, we present two metastatic melanoma patients with copy number variations (CNVs) of cyclin dependent kinase 4 (CDK4) pathway-related genes, who had failed in previous chemotherapy or immunotherapy, were treated with CDK4/6 inhibitor palbociclib and achieved tumor control for over 6 months. The copy number of CDK4, CCND1 and P16INK4a of one patient was 3.6, 3, 2 copies, and for the other patient, the copy number was 3, 2, 1 respectively. It indicates that CDK4 may be a potential target for melanoma.